Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.

For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding have minimal effects on hepatic clearance. Such drugs are classified as capacity-limited and binding-insensitive. Conversely, drugs highly bound to plasma protein are considered capacity-limited and binding-sensitive. Even slight alterations in protein binding can lead to a notable increase in the free drug concentration, resulting in an elevated drug metabolism rate and hepatic clearance.

Furthermore, any drug metabolized and eliminated by the liver can be categorized on a triangular graph. This graph helps identify how two pharmacokinetic parameters—hepatic extraction ratio and percent plasma protein binding, influence hepatic drug metabolism. For example, propranolol has a high hepatic extraction ratio and relatively low plasma protein binding. It falls closer to the flow-limited corner of the triangle. This means its hepatic clearance primarily depends on liver blood flow, and changes in liver perfusion significantly affect its metabolism and elimination.

In contrast, warfarin has a low hepatic extraction ratio and high plasma protein binding. It would be located near the capacity-limited, binding-sensitive corner of the triangle. For drugs like warfarin, hepatic clearance is influenced more by plasma protein binding and enzyme activity than by liver blood flow.

The closer a drug falls to a corner of the triangle, the more likely it is to exhibit characteristic changes in disposition during liver disease. Propranolol's clearance may decrease due to reduced blood flow, while warfarin's clearance may change due to protein binding or enzyme activity alterations.

This highlights the importance of understanding a drug's position within this framework for predicting drug behavior in conditions affecting hepatic function.